Bellinger Andrew

Bellinger Andrew serves as the Chief Scientific Officer at Verve Therapeutics, Inc., a company focused on gene editing technologies for cardiovascular disease. His recent activity includes two public disclosures reported through SEC Form 4 filings as of February 16, 2024. The disclosed trading record indicates a total reported amount of $2.3 million, primarily related to his role at Verve Therapeutics, Inc. (VERV), with the largest move being a grant/exercise valued at approximately $2.3 million.